Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment

Voß, Karsten; Falke, Karen; Bernsdorf, Arne; Grabow, Niels; Kästner, Christian; Sternberg, Katrin; Minrath, Ingo; Eickner, Thomas; Wree, Andreas; Schmitz, Klaus‐Peter; Guthoff, Rudolf; Witt, Martin; Hovakimyan, Marina

doi:10.1016/j.jconrel.2015.06.035

Cited by 29 publications

(25 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A formulation of HA crosslinked with isocyanate-functionalized 1,2-ethylene glycol bis(dilactic acid) was generated and loaded with latanoprost. After subconjunctival administration, latanoprost release was extended for up to 160 days, but complete biodegradation of the material required an additional four months [178].…”

Section: Subconjunctival Deliverymentioning

confidence: 99%

Polysaccharides in Ocular Drug Delivery

et al. 2019

View full text Add to dashboard Cite

Polysaccharides, such as cellulose, hyaluronic acid, alginic acid, and chitosan, as well as polysaccharide derivatives, have been successfully used to augment drug delivery in the treatment of ocular pathologies. The properties of polysaccharides can be extensively modified to optimize ocular drug formulations and to obtain biocompatible and biodegradable drugs with improved bioavailability and tailored pharmacological effects. This review discusses the available polysaccharide choices for overcoming the difficulties associated with ocular drug delivery, and it explores the reasons for the dependence between the physicochemical properties of polysaccharide-based drug carriers and their efficiency in different formulations and applications. Polysaccharides will continue to be of great interest to researchers endeavoring to develop ophthalmic drugs with improved effectiveness and safety.

show abstract

Section: Subconjunctival Deliverymentioning

confidence: 99%

Polysaccharides in Ocular Drug Delivery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For both compounds (6 and 9) the acidic hydrogen (H 1 ) were not observed due to the salt formation, although it was distinguishable in 3 1 H NMR spectrum ( Figures S1, S4, S6). 13 C NMR spectra of 6 and 9 exhibit thirteen and twelve resonances, respectively (Figures S5 and S7, Tables 2 and 3 131 (C 9 ) and 142 (C 10 ) could be assigned to the carbons of SAMAL -group of all compunds moiety. Five peaks for 6 at d 159 (C 14 ), 138 (C 15 ), 109 (C 16 ), 112 (C 17 ) and 147 (C 18 ) could be assigned to the carbons of (HAP) + ring moiety.…”

Section: Resultsmentioning

confidence: 99%

“…8 As a result, elevation in intraocular pressure (IOP) causes gradual loss of visual field called as glaucoma. [10][11][12] One of the methods used in glaucoma treatment is to reduce the production of aqueous humor 10,13 by using carbonic anhydrase inhibitors. 4,5,11,13,14 2-Aminopyridines and benzimidazoles serve as useful chelating ligands in a variety of inorganic and organometallic applications, [15][16][17] and also act as monodentate ligands which coordinate the metal ions through the nitrogen of the ring [16][17][18][19][20][21] in most cases.…”

Section: Introductionmentioning

confidence: 99%

Preparation of Two Maleic Acid Sulfonamide Salts and Their Copper(II) Complexes and Antiglaucoma Activity Studies

Yenikaya

İlkimen

Demirel

et al. 2016

Journal of the Brazilian Chemical Society

View full text Add to dashboard Cite

Two novel proton transfer compounds (HAP) + (SAMAL) -and (HBI) + (SAMAL) -.H 2 O were obtained from (E)-4-oxo-4-(4-sulfamoylphenylamino)but-2-enoic acid (HSAMAL) and 2-aminopyridine (AP) or 1H-benzimidazole (BI), respectively. Copper(II) complexes of salts and of HSAMAL have also been prepared. They have been characterized by elemental, spectral, thermal analyses, magnetic measurement and molar conductivity. Human carbonic anhydrase isozymes (hCA I and hCA II) were purified from erythrocytes by using affinity chromatography as 84.40 and 188.71 fold, respectively. The inhibitory effects of synthesized compounds and acetazolamide (AAZ, control compound) on the hydratase and esterase activities of hCA isozymes have been studied as in vitro to find out their antiglaucoma potentials. The inhibition constant (K i ) values of the compounds were in the range of 0.18 ± 0.007 to 10.24 ± 0.014 µmol L -1 for hCA I, and 0.12 ± 0.004 to 130.11 ± 0.021 µmol L -1 for hCA II.

show abstract

“…5). 12 The in vitro degradation rate of weight loss of Ologen-6 and Ologen-7 showed dramatically different tendencies. For comparative analyses, the rate constants (k) of the collagenase hydrolysis of Ologen-6 and Ologen-7 were obtained from the initial weight loss slope of the plots in Figure 5A.…”

Section: Enzymatic Degradation Rates Of Ologen-6 and Ologen-7mentioning

confidence: 98%